Search results for "recurrence"

showing 10 items of 1036 documents

Panniculitis due to potassium bromide.

1998

Potassium bromide again is well known to be surprisingly effective in patients with severe myoclonic epilepsy in infants (SME). Rare side effects on the skin reappeared, such as the febrile nodular panniculitis (Weber-Christian syndrome). In 1993 we described the first three cases of necrotizing panniculitis and introduced the term 'halogen panniculitis'. It is a systemic disease with crops of subcutaneous nodules, fever, elevated sedimentation rate, hepatosplenomegalia, and abdominal pain. Later severe necrosis of the skin and adipose tissue may happen with deep ulcerations. History and course of five cases, described in this paper, suggest either an allergy or toxic reason. Histologic pic…

BromidesMaleSystemic diseaseAbdominal painPathologymedicine.medical_specialtyAllergyNecrosisPanniculitisAdolescentPotassium CompoundsAdipose tissueInflammationSkin DiseasesDevelopmental NeuroscienceRecurrenceSkin UlcermedicineHumansChildRetrospective StudiesEpilepsybusiness.industryGeneral Medicinemedicine.diseaseChild PreschoolPediatrics Perinatology and Child HealthMyoclonic epilepsyAnticonvulsantsFemaleNeurology (clinical)medicine.symptomPanniculitisbusinessBraindevelopment
researchProduct

Angiogenesis-related prognosis in patients with oral squamous cell carcinoma-role of the VEGF +936 C/T polymorphism.

2014

BACKGROUND: The aim of the study was the immunohistological assessment of VEGF-single nucleotide polymorphism (SNP)-related angiogenic activity in oral squamous cell carcinoma (OSCC) in correlation with prognosis. METHODS: Fifty OSCC samples were immunostained with CD31-antibodies. Mean microvessel density (MVD) and staining intensity were determined and associated with clinicopathological/prognostic features as well as with the VEGF +936C/T SNP. RESULTS: A significant higher MVD could be seen for T3 and T4 compared with T1 and T2, N > 0 vs. N0 as well as G3–G4 vs. G1–G2 OSCCs (all: P < 0.05). A higher MVD was also associated with increased and earlier rates of local relapses, more metastas…

CD31AdultMaleVascular Endothelial Growth Factor ACancer Researchmedicine.medical_specialtyPathologyAngiogenesisVEGF receptorsSingle-nucleotide polymorphismBiologyGastroenterologyPolymorphism Single NucleotideDisease-Free SurvivalPathology and Forensic MedicineInternal medicinemedicineSNPHumansAlleleAgedAged 80 and overNeovascularization PathologicSquamous Cell Carcinoma of Head and NeckNeoplasms Second PrimaryMiddle AgedPrognosisImmunohistochemistryStainingSurvival Ratestomatognathic diseasesOtorhinolaryngologyHead and Neck NeoplasmsLymphatic Metastasisbiology.proteinCarcinoma Squamous CellPeriodonticsFemaleMouth NeoplasmsOral SurgeryNeoplasm Recurrence LocalImmunostainingJournal of oral pathologymedicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
researchProduct

Relapses of idiopathic inflammatory myopathies after vaccination against COVID-19: a real-life multicenter Italian study

2022

AbstractSevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination plays a crucial role as pivotal strategy to curb the coronavirus disease-19 (COVID-19) pandemic. The present study described the clinical status of patients affected by idiopathic inflammatory myopathies (IIM) after COVID-19 vaccination to assess the number of relapses. We included all patients affected by IIM and followed by Myositis Clinic, Rheumatology and Respiratory Diseases Units, Siena University Hospital, Bari University Hospital, Policlinico Umberto I, Sapienza University, Rome, and Policlinico Paolo Giaccone, Palermo. They underwent a telephone survey. A total of 119 IIM patients (median, IQR 58 (47–6…

COVID-19 VaccinesMyositisCOVID-19 vaccinationSARS-CoV-2VaccinationCOVID-19Relapses.RecurrenceEmergency MedicineInternal MedicineHumansCOVID-19 vaccination; Idiopathic inflammatory myopathies; RelapsesIdiopathic inflammatory myopathiesIdiopathic inflammatory myopathieRelapses
researchProduct

Recurrences following treatment of proliferative verrucous leukoplakia: A systematic review and meta-analysis.

2021

Objective A systematic review and meta-analysis was made of the incidence of recurrences in patients with proliferative verrucous leukoplakia subjected to different types of treatment. Methods The study was carried out following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines. A literature search was made in the Medline (PubMed), EMBASE and Web of Science databases, together with a manual search, covering the period from 1985 to January 2020, with no language restrictions. Studies were included if they described treatments applied to at least 10 patients with the corresponding outcomes. Methodological quality was evaluated using Jadad sca…

Cancer ResearchFunnel plotmedicine.medical_specialtyMEDLINEPathology and Forensic Medicine03 medical and health sciences0302 clinical medicinemedicineHumansbusiness.industryIncidence (epidemiology)Incidence030206 dentistryPublication biasMiddle AgedRandom effects modelDermatologyJadad scaleSystematic reviewOtorhinolaryngology030220 oncology & carcinogenesisMeta-analysisPeriodonticsFemaleOral SurgeryLeukoplakia OralNeoplasm Recurrence LocalbusinessJournal of oral pathologymedicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral PathologyREFERENCES
researchProduct

Deletion of the PER3 Gene on Chromosome 1p36 in Recurrent ER-Positive Breast Cancer

2010

El pdf del artículo es la versión de autor.-- et al.

Cancer ResearchMicroarrayGene DosageGene ExpressionEstrogen receptorBreast NeoplasmsGene dosageMiceBreast cancerOriginal ReportsAnimalsHumansMedicineGenetic Predisposition to DiseaseCopy-number variationskin and connective tissue diseasesSequence Deletionbusiness.industryCancerPeriod Circadian ProteinsPrognosismedicine.diseaseSurvival AnalysisDisease Models AnimalReceptors EstrogenOncologyChromosomes Human Pair 1Cancer researchFemaleBreast diseaseNeoplasm Recurrence LocalbusinessTamoxifenmedicine.drugJournal of Clinical Oncology
researchProduct

Underuse of long-term routine hospital follow-up care in patients with a history of breast cancer?

2011

Abstract Background After primary treatment for breast cancer, patients are recommended to use hospital follow-up care routinely. Long-term data on the utilization of this follow-up care are relatively rare. Methods Information regarding the utilization of routine hospital follow-up care was retrieved from hospital documents of 662 patients treated for breast cancer. Utilization of hospital follow-up care was defined as the use of follow-up care according to the guidelines in that period of time. Determinants of hospital follow up care were evaluated with multivariate analysis by generalized estimating equations (GEE). Results The median follow-up time was 9.0 (0.3-18.1) years. At fifth and…

Cancer ResearchPediatricsMultivariate analysisAftercareComorbidityGUIDELINESGeelaw.inventionCohort StudiesRandomized controlled triallawNetherlandsAged 80 and overSURVIVORSmedicine.diagnostic_testBreast neoplasmFollow-upNeoplasms Second PrimaryMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCombined Modality TherapyUtilizationOncologyPractice Guidelines as TopicRECURRENCESHormonal therapyFemaleGuideline AdherenceHEALTHResearch ArticleCohort studyMammographyAdultmedicine.medical_specialtyOutpatient Clinics HospitalAntineoplastic Agents HormonalMatched-Pair AnalysisBreast Neoplasmslcsh:RC254-282Breast cancerGeneticsmedicineHumansMammographyMETAANALYSISAgedbusiness.industryPatient Acceptance of Health Caremedicine.diseaseComorbidityTRENDSRANDOMIZED-TRIALHealth Care SurveysPhysical therapyPatient ComplianceUPDATESURVEILLANCE MAMMOGRAPHYbusinessFollow-Up Studies
researchProduct

Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controv…

2016

Contains fulltext : 171468pub.pdf (Publisher’s version ) (Open Access) Primary treatment of rectal cancer was the focus of the second St. Gallen European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Cancer Conference. In the context of the conference, a multidisciplinary international expert panel discussed and voted on controversial issues which could not be easily answered using published evidence. Main topics included optimal pretherapeutic imaging, indication and type of neoadjuvant treatment, and the treatment strategies in advanced tumours. Here we report the key recommendations and summarise the related evidence. The treatment strategy for localised rect…

Cancer ResearchStagingColorectal cancermedicine.medical_treatmentNeoplasias Gastrointestinais030230 surgerySYNCHRONOUS LIVER METASTASESImagingCOLORECTAL-CANCER0302 clinical medicineADJUVANT CHEMOTHERAPYTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]SHORT-COURSE RADIOTHERAPYRectal cancerNeoadjuvant therapyGastrointestinal NeoplasmsRectal Neoplasms/drug therapyCombination chemotherapyChemoradiotherapyCombined Modality TherapyTotal mesorectal excisionNeoadjuvant TherapyEuropeNeoplasias do Recto/quimioterapiaOncology030220 oncology & carcinogenesisMEDIAN FOLLOW-UPLife Sciences & BiomedicineDiagnostic Imagingmedicine.medical_specialtyAntineoplastic AgentsLOCAL RECURRENCERisk AssessmentCOURSE PREOPERATIVE RADIOTHERAPY03 medical and health sciencesmedicineHumansGastrointestinal cancerOncology & CarcinogenesisRadiochemotherapyNeoplasm StagingScience & TechnologyRadiotherapyRectal Neoplasmsbusiness.industryGeneral surgeryTOTAL MESORECTAL EXCISIONCancerRANDOMIZED PHASE-IIImedicine.diseaseSurgeryRadiation therapySurgerybusiness1112 Oncology And CarcinogenesisChemoradiotherapyPOSTOPERATIVE CHEMORADIOTHERAPY
researchProduct

T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas

2021

Abstract Purpose: Gliomas are intrinsic brain tumors with a high degree of constitutive and acquired resistance to standard therapeutic modalities such as radiotherapy and alkylating chemotherapy. Glioma subtypes are recognized by characteristic mutations. Some of these characteristic mutations have shown to generate immunogenic neoepitopes suitable for targeted immunotherapy. Experimental Design: Using peptide-based ELISpot assays, we screened for potential recurrent glioma neoepitopes in MHC-humanized mice. Following vaccination, droplet-based single-cell T-cell receptor (TCR) sequencing from established T-cell lines was applied for neoepitope-specific TCR discovery. Efficacy of intravent…

Cancer ResearchT-LymphocytesT cellCellchemical and pharmacologic phenomenaRecurrent GliomaMajor histocompatibility complexImmunotherapy AdoptiveMiceGliomamedicineAnimalsMHC class IIReceptors Chimeric AntigenbiologyELISPOTT-cell receptorGliomamedicine.diseaseDisease Models Animalmedicine.anatomical_structureOncologybiology.proteinCancer researchImmunotherapyNeoplasm Recurrence LocalClinical Cancer Research
researchProduct

Long-term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides.

2002

We report here on 2 patients who received adjuvant vaccination with an HLA-A2- or HLA-A24-restricted tyrosinase peptide, respectively, and GM-CSF for frequently relapsing stage IV melanoma. Following resection of metastases and irradiation of brain metastases in 1 patient, both patients were without evidence of disease when receiving the first vaccination. While the patients had had 9 and 12, respectively, mostly s.c., relapses during the 3 years before vaccination, they experienced freedom from relapse for more than 2 years after vaccination. We found a T-cell response to the vaccine peptide in both patients in the peripheral blood by ex vivo IFN-gamma ELISPOT assay. The T-cell population …

Cancer ResearchTime FactorsCD3 Complexmedicine.medical_treatmentCD8 AntigensT-LymphocytesPopulationTyrosinase PeptideCancer VaccinesPolymerase Chain ReactionDisease-Free SurvivalEpitopesInterferon-gammaRecurrencemedicineHumansRNA MessengerNeoplasm MetastasiseducationMelanomaeducation.field_of_studybiologybusiness.industryBrain NeoplasmsMonophenol MonooxygenaseMelanomaELISPOTImmunotherapymedicine.diseaseFlow CytometryImmunohistochemistryVaccinationOncologyGranzymeImmunologybiology.proteinbusinessPeptidesCD8International journal of cancer
researchProduct

Follow-up of patients with colonic polyps containing severe atypia and invasive carcinoma. Compliance, recurrence, and survival

1988

Between January 1975 and December 1984 1769 polyps were endoscopically removed from 1219 patients. Eight percent of these patients had polyps containing severe atypia and 5.0% had polyps containing invasive cancer. A close postoperative surveillance program was followed by only a few patients, but compliance improved with longer follow-up intervals. Metachronous polyps were observed with similar frequency in patients with benign polyps (34.8%) and those with polyps containing severe atypia (23.8%) or cancer (41.7%). Patients in whom malignant polyps were endoscopically removed had a 5-year survival rate of 84.3% that did not differ from that of patients' whose polyps contained severe atypia…

Cancer Researchmedicine.medical_specialtyColonic PolypsGastroenterologyActuarial AnalysisInternal medicineotorhinolaryngologic diseasesmedicineAtypiaCarcinomaHumansNeoplasm InvasivenessPatient complianceneoplasmsSurvival rateAgedRetrospective StudiesInvasive carcinomaEpitheliomabusiness.industryCarcinomaCancerEndoscopypathological conditions signs and symptomsMiddle Agedmedicine.diseasedigestive system diseasesBenign polypsSurgerysurgical procedures operativeOncologyPopulation SurveillancePatient ComplianceNeoplasm Recurrence LocalbusinessFollow-Up StudiesCancer
researchProduct